Insights

Conference Coverage

Anti PD-1 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancers

05/18/2024

Ryan Moy, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of anti PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Claudin-18.2 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancer

05/18/2024

Samuel Cytryn, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, discussed first-line use of claudin-18.2 inhibitors for patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology

Conference Coverage

The Case Against Antibody Drug Conjugates for Patients With Lung Cancers

05/15/2024

Corey Langer, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.

At the Great Debates and Updates...

05/15/2024

Oncology

Conference Coverage

Routine Screening for Brain Metastases Among Patients With HER2-Positive Breast Cancer

05/14/2024

Laura Huppert, MD

At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.

At Great Debates and Updates in...

05/14/2024

Oncology

Conference Coverage

Should Pemetrexed Be Continued in Patients Who Receive the KEYNOTE-189 Regimen?

05/14/2024

Featuring Edward Garon, MD, MS

Featuring Edward Garon, MD, MS ...

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.

At the Great Debates and Updates...

05/14/2024

Oncology

Conference Coverage

Advantages to Continuing Pemetrexed as Maintenance Therapy in the KEYNOTE-189 Regimen

05/14/2024

Corey Langer, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.

At the Great Debates and Updates...

05/14/2024

Oncology

Videos

Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

05/10/2024

Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.

Samantha Shenoy, NP, discusses...

05/10/2024

Oncology

Seth Wander, MD, PhD, Massachusetts General Hospital

Videos

Novel Endocrine Agents for Patients With HR-Positive Breast Cancer

05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...

At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Denise Yardley, MD, Sarah Cannon Research Institute

Videos

Is Age 50 Relevant for Decisions in Early HR-Positive Breast Cancer?

05/08/2024

Featuring Denise Yardley, MD

At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Recent News

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Datopotamab Deruxtecan Shows Promising Activity, Safety Among Heavily Pretreated Patients With HR-Positive, HER2-Negative, or Triple-Negative Breast Cancer

05/14/2024

Stephanie Holland

According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...

According to results from the...

05/14/2024

Oncology

News

Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma

05/10/2024

Stephanie Holland

Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.

Results from a prospective,...

05/10/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology